Modeling the selective growth advantage of genetically variant human pluripotent stem cells to identify opportunities for manufacturing process control (2024)
Attributed to:
Developing Efficient Models to Define Economic and Low Risk High Value Manufacture of Cell Based Products
funded by
EPSRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.jcyt.2024.01.010
Publication URI: http://dx.doi.org/10.1016/j.jcyt.2024.01.010
Type: Journal Article/Review
Parent Publication: Cytotherapy